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To determine the ability of clinical measures of balance to distinguish fallers from non-
fallers and to determine their predictive validity in identifying those at risk of falls. 
Data Sources 
AMED, CINAHL, Medline, Scopus, PubMed Central and Google Scholar. 
First search: July 2015. Final Search: October 2017. 
Review Methods 
Inclusion criteria were studies of adults with a definite Multiple Sclerosis diagnosis, a clinical 
balance assessment and method of falls recording. Data were extracted independently by 
two reviewers. Study quality was assessed using the QUADAS-2 scale and the modified 
Newcastle-Ottawa Quality Assessment Scale. Statistical analysis was conducted for the 
cross-sectional studies using Review Manager 5. The mean difference with 95% confidence 
interval in balance outcomes between fallers and non-fallers was used as the mode of 
analysis.  
Results 
We included 33 studies (19 cross sectional, 5 randomised controlled trials, 9 prospective) 
with a total of 3901 participants, of which 1917 (49%) were classified as fallers. The balance 
measures most commonly reported were the Berg Balance Scale, Timed Up and Go and Falls 
Efficacy Scale- International. Meta-analysis demonstrated fallers perform significantly worse 
than non-fallers on all measures analysed except the Timed Up and Go Cognitive (p<0.05), 
but discriminative ability of the measures is commonly not reported.  Of those reported the 
Activities Balance Confidence Scale had the highest AUC value (0.92), but without reporting 
corresponding measures of clinical utility. 
Conclusion 
Clinical measures of balance differ significantly between fallers and non-fallers but have 














Previous studies have found falls prevalence to be as high as 56% among people with 
Multiple Sclerosis,  with 37% of those falling classed as frequent fallers 1. Injurious falls can 
be serious in this group 2 and both the high rate of falls and high levels of concern about 
falling may lead to activity curtailment and further reductions in physical fitness and 
endurance 3. Several factors have been shown to be associated with an increased risk of falls 
in Multiple Sclerosis 4 including longer disease duration, more progressive disease course, 
use of a mobility device, slower gait speed and impaired balance. Having a balance 
impairment has a pooled odds ratio of 1.07 (95% CI 1.04 - 1.10) for falls among people with 
Multiple Sclerosis5 . While these earlier reviews 4, 5 have identified that impaired balance is 
associated with increased falls risk no systematic review to date has examined the 
predictive validity of the various clinical measures of balance used to identify falls risk.  
 
A wide range of clinical tests and self-report measures have been used to evaluate balance 
and falls risk in Multiple Sclerosis 6-9 using different observational methods. The 
International Multiple Sclerosis Falls Prevention Research Network (IMSFPRN) 
recommended the assessment of dynamic balance 10 in falls prevention research,  but it 
acknowledged there is not enough evidence to specifically recommend one measure over 
any other. Thus, the objective of this systematic review and meta-analysis is to investigate 
the relationship between clinical balance measures, and falls in people with Multiple 
Sclerosis. Firstly, we will examine if clinical balance measures demonstrate different scores 
in fallers and non-fallers in cross sectional studies of people with Multiple Sclerosis and 
secondly, we will determine the discriminative ability and clinical utility for assessing falls in 
prospective cohort studies. We hypothesise that there will be a significant difference 
between scores in fallers and non-fallers on these clinical balance measures and that 
measures with an area under the receiving operating curve statistic value of 0.7 or greater 




This study consists of a systematic review and meta-analysis. The Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) 11 standardised reporting guidelines were 
followed to ensure the standardised conduct and reporting of the research. The MOOSE 
checklist for meta-analyses of observational studies is available in online appendix 1.  A 
systematic literature search was conducted by the primary author (GQ, PhD candidate), with 
the first search carried out in July 2015 and the final search carried out in October 2017, and 
included the following databases; AMED, CINAHL, Medline (through EBSCO search 
platform), Scopus and PubMed Central. Keywords were formed by examining the search 
strategy in other systematic reviews in this area and by checking citations and keywords 
from results of a preliminary search in Google Scholar. The keywords and MeSH headings 
utilised as search terms were: ‘multiple sclerosis’ OR ‘MS’ AND ‘balance’ OR ‘postural 
control’ OR ‘postural instability’ OR ‘imbalance’ OR ’stability’ AND ‘fall*’ OR ‘fall risk’. The 
search was supplemented through the searching of references lists of returned articles and 
the use of the same search terms in Google Scholar. No restrictions were placed on 
language or year of publication. See online appendix 2 for more details of search strategy. 
 
Inclusion criteria were studies of adults with a definite Multiple Sclerosis diagnosis, use of a 
clinical balance measure and a method of falls reporting. Cross-sectional studies were 
included where fallers were compared to non-fallers and prospective cohort studies were 
also included where balance measures were administered prior to a subsequent falls event. 
Baseline data from randomised controlled trials was suitable for inclusion in the meta-
analysis if authors provided the relevant data when contacted and if falls were an outcome 
of interest in the study. Studies were excluded from this review if laboratory based 
measures only were used (e.g. limits of stability using the Smart Balance Master or static 
posturography using force platforms) or if the cohort consisted of a mixed neurological 
population. 
Two reviewers (GQ and SC) read the titles and/or abstracts of the identified studies and 
discarded irrelevant studies. Studies considered to be eligible for inclusion were read in full 
and their suitability for inclusion was determined independently by two reviewers (GQ, SC). 
Where disagreement occurred, discussions took place until consensus was reached. Authors 
were contacted to provide supplementary information when insufficient data were 
provided in the publication. If two studies were found to involve the same patient cohort, 
only one study was included in the meta-analysis. Information relating to authors and year 
of publication, study design and setting, eligibility criteria, population demographics and 
outcomes of balance measures were extracted to provide summary tables.  
 
The quality of included prospective cohort studies was assessed using the validated 
QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) Scale 12. The tool considers 
risk of bias and applicability concerns and consists of four main domains- patient selection, 
index test, reference standard, and flow of patients through the study including timing of 
the index test and reference standard. Risk of bias is judged as ‘low’, ‘high’ or ‘unclear’. The 
quality of the cross sectional studies was assessed using the Newcastle-Ottawa Quality 
Assessment Scale adapted for cross sectional studies 13. It involves three sub-sections: the 
selection of cases, the comparability of different outcome groups and the outcome itself. A 
star system is used to allow a semi-quantitative assessment of study quality and a maximum 
score of ten stars may be awarded depending on the criteria level the study meets in each 
section. Two of the authors (GQ and LC) independently assessed the methodological quality 
of the studies. Where disagreement occurred, deliberation took place until consensus was 
reached.  
Meta-analysis of the prospective cohort studies was not possible due to the heterogeneous 
nature of the outcomes administered and the variability in follow-up time-points. However, 
the findings of these studies are summarised relating to the discriminative ability and clinical 
utility of the balance measures. Discrimination, the ability of a measure to differentiate 
between individuals with and without falls, was quantified using the area under the receiver 
operating characteristic curve statistic. A value of 0.5 represents chance, values between 0.7 
and 0.9 represent moderate discrimination and a value of 1 represents perfect 
discrimination 14. The clinical utility of the outcome measures was assessed using the 
summary estimates of sensitivity and specificity.  
 
Statistical analysis was conducted for the cross-sectional studies with retrospectively 
collected falls data using Review Manager 5 (Version 5.3). The mean difference (MD) with 
95% confidence interval in balance outcomes between fallers and non-fallers was used as 
the mode of analysis. We addressed the impact of sample size by estimating a weighting 
factor for each study, and assigning larger effect-weights in studies with larger samples. 
Heterogeneity was examined using the I2 statistic. We used the Cochrane interpretation of 
these values where an I2 value of 30% to 60% indicates moderate heterogeneity and an I2 of 
50% to 90% demonstrates substantial heterogeneity 15. When the pooled data indicated 
moderate or substantial heterogeneity, we completed our meta-analysis using the more 
conservative random-effects modelling (REM) approach instead of the fixed-effects model 
(FEM). Where reported outcomes had a scale where a lower value is indicative of a better 
outcome, the reported values were multiplied by -1 so that in all analyses a higher value 
indicated a better outcome16 . 
 
Results    
 
Study Selection 
Figure 1 shows the flow of studies through the review selection process. Of the 33 studies 
eligible for inclusion, nine were prospective cohort studies 17-19 20-25 ,19 were cross-sectional 
studies 6, 8, 26-42 and five were randomised controlled trials with appropriate cross sectional 
data 43-47. Twelve authors were contacted for additional data, ten of whom returned data in 
relation to twelve different studies. Both fall definition and numbers of falls needed to be 
classified as a faller varied widely across the included studies with seven different fall 
definitions reported and two faller classifications, see online appendix 3 and 4. 
 
A detailed summary of included studies is provided in online supplementary appendix 3 
(prospective studies) and online supplementary appendix 4 (cross sectional studies). Within 
the prospective studies the participant numbers in the Multiple Sclerosis group ranged 
across studies from 38 20  to 416 participants 24 with a total of 1223 Multiple Sclerosis 
participants across the nine prospective studies. The range of mean ages reported by the 
prospective studies for people with Multiple Sclerosis was 30.29 years 18  to 57 years 21   and 
six of the nine studies reported mean disease duration with averages ranging from 4.02 
years 18  to 14.37 years 20 . The mean Expanded Disability Status Scale scores ranged from 
2.8 17 to 5 23. The duration of falls recording using falls diaries or calendars varied from 3 
months 21, 23, 24 to 12 months 20, 22. The incidence of falls across these studies ranged from 
41% 24 to 71% 17 with a mean incidence of 56% across the nine studies. 
 
 The participant numbers in the cross sectional studies and randomised controlled trials 
varied from 12 33 to 402 38 with a total number of 2,678 across the 24 studies. The mean 
ages reported ranged from 40 years 31 to 59 years 46 and mean disease duration was 
reported in 20 of these studies with averages ranging from 4.3 years 31 to 20.85 years 47 . 
Expanded Disability Status Scale score was reported by 16 studies and the mean score 
ranged from 1.7 31, 39 to 6.11 47 . Fallers were identified using a falls history ranging from one 
month recall 6 to 12 months 8, 26, 32, 36, 38-42. The prevalence of falls across these studies 
ranged from 23% 27 to 76% 36, with an overall prevalence of 46%.  
 
Balance Measures 
Self-report balance measures utilised across all studies include the Falls Efficacy Scale 
International (N=9), Activities-specific Balance Confidence Scale (N=7), Dizziness Handicap 
Inventory (N=1) and the Survey of Activities and Fear of Falling in the Elderly (N=1). Clinical 
measures included the Berg Balance Scale (N=12), Dynamic Gait Index (N=6), Timed Up and 
Go test (N=11), Timed Up and Go cognitive  (N=3), the mini BESTest (N=2), the Four Square 
Step test (FSST) (N=6),  Lindmark Motor Capacity Assessment subscale for balance (N=1), the 
Balance Evaluations System Test (N=1), the Equiscale test (N=1), Functional Reach (N=1), 
Physiological Profile Assessment (N=2) and the Six Spot Step test (N=1). The Berg Balance 
Scale and Timed Up and Go were the measures most commonly used and in combination 
with the Activities-Specific Balance Confidence scale, Falls Efficacy Scale International, 
Dynamic Gait Index, Four Square Step test, Timed Up and Go Cognitive and mini BESTest 
provided appropriate data for meta-analysis. 
 
Quality Assessment  
A detailed overview of the methodological quality of the 33 studies is provided in Tables 1a 
(cohort studies) and 1b (cross-sectional studies and randomised controlled trials). In the two 
QUADAS-2 domains of patient selection and reference standard, all nine prospective studies 
showed low risk of bias in relation to applicability, indicating an appropriate cohort was 
studied with a suitable method of falls recording. No study demonstrated a low risk of bias 
in all domains with only one study 23 achieving a low risk of bias in six of the seven domains. 
The total scores on the modified Newcastle Ottawa Scale ranged from 3 stars 26 to 8 stars 28, 
44 across the cross-sectional studies. One of the studies was classified as high risk of bias (1-3 
stars)26 and nine of the studies (14%) were medium risk (4-5 stars) with the remaining 
fourteen studies (81%) classed as low risk of bias (6-9 stars).  
 
In relation to the discriminative ability of the clinical measures, Table 2 presents the results 
of the studies.  Only two studies reported the area under the receiving operating 
characteristic curve statistic, the sensitivity, specificity and cut off value 19, 25.  Of the ten 
clinical balance measures investigated in the cohort studies, the Berg Balance Scale was one 
of the most commonly reported measures and was the only measure with both an area 
under the receiver operating characteristic curve statistic value of greater than 0.7 20 and a 
sensitivity of greater than 80% 23. However, another study reported a conflicting sensitivity 
score for the Berg Balance Scale of 32% 24. The other two measures with reported area 
under the receiver operating characteristic curve statistic values of greater than 0.7 were 
the Activities Balance Confidence Scale and The Falls Efficacy Scale International 18 but with 
no corresponding sensitivity or specificity values. 
 
Meta-analysis of Cross-Sectional Studies- 
Results of the meta-analysis for clinical measures are displayed in Figure 2. Ten studies used 
the Berg Balance Scale 48  to compare balance across fallers and non-fallers 6, 27, 33, 35, 41, 43-47. 
Fallers demonstrated significantly lower balance scores than their counterparts without a 
history of falls, as presented in Figure 2a (FEM, MD = 2.72, 95% CI {1.53-3.92}, P<0.01, I2 = 
30%). Three of the studies 27, 41, 47 included in the meta-analysis for this measure had an 
overall medium risk of bias based on methodological quality- score, the other eight were 
deemed low risk of bias (Newcastle Ottawa Scale score of 6 to 8).  
 
The Dynamic Gait Index 49 was used in five studies 6, 27, 29, 34, 43. The findings from these 
pooled studies (Figure 2b) demonstrate that fallers report significantly lower DGI scores 
than non-fallers and two 27, 34 of the five studies included had a medium risk of bias. Five of 
the nine studies included in meta-analysis for the Timed Up and Go 50 had a medium risk of 
bias, with the remaining studies demonstrating a low risk of bias and the pooled meta-
analysis did demonstrate a significant difference between fallers and non-fallers on this 
measure (Figure 2c). 
 
Results for the Timed Up and Go Cognitive 51, mini BESTest 52 and Four-Square Step test 53 
are seen in Figures 2d, 2e and 2f respectively. All measures showed a significant difference 
across fallers and non-fallers except for the Timed Up and Go Cognitive.  The findings from 
the meta-analysis for the Timed Up and Go Cognitive, Mini BESTest and Four-Square Step 
test should be interpreted with caution as they had only small numbers of studies suitable 
for inclusion (two to four for each analysis).  
 
Findings from the meta-analysis for subjective measures, the Activities Specific Balance 
Confidence Scale 54 and the Falls Efficacy Scale International 55 are seen in Figure 3a and 3b 
(online supplementary data). A significant difference across fallers and non-fallers was 
noted for both these measures. The meta-analysis for both these measures included one 
study with an overall medium risk of bias and this must be remembered when interpreting 




In this review exploring the differences in balance between fallers and non-fallers with 
Multiple Sclerosis and the discriminative ability and clinical utility of clinical balance 
measures for falls prediction, we found a total of 33 studies suitable for inclusion. The most 
commonly reported clinical measures were the Berg Balance Scale, the Timed Up and Go, 
Activities Specific Balance Confidence Scale and Falls Efficacy Scale International. These 
measures do demonstrate a significant difference between fallers and non-fallers but have 
conflicting sensitivity values reported and often no area under the receiver operating 
characteristic curve statistic value reported or poor discriminative ability demonstrated.  
There is currently insufficient evidence from the nine prospective studies to support any 
balance measure as a falls prediction tool for people with Multiple Sclerosis.  
 
From the limited number of prospective studies, there were only three reported measures 
demonstrating an area under the receiver operating characteristic curve statistic value of 
moderate discrimination; the Activities Balance Confidence Scale 18, the Falls Efficacy Scale 
International 18 and the Berg Balance Scale 20. No study reported corresponding sensitivity 
and specificity values together with the area under the receiver operating characteristic 
curve statistic value for these measures, but two different studies did report conflicting 
sensitivity values for the Berg Balance scale with one study reporting a high sensitivity value 
(greater than 80%) 23 and another study reporting a contrasting sensitivity value of 32% 24. 
This conflicting value may be due to the variance in study population in the two cohorts with 
the latter study’s participants representing a milder disease stage and a younger age profile  
than the former study 23. The Berg Balance Scale should not be used to identify falls risk in 
Multiple Sclerosis until there is a stronger evidence base available demonstrating good 
discriminative ability and satisfactory clinical utility.  
 
Our results are somewhat similar to a previous review by Gianni et al 4, who found that 
measures such as the Berg Balance Scale and Timed Up and Go demonstrated poorer 
performance in fallers when compared to non-fallers. However, those authors meta-
analysed data from both prospective and cross-sectional studies, thus diluting the validity of 
their pooled results. Gunn et al 5 looked at risk factors associated with falls in Multiple 
Sclerosis and found that balance impairment was associated with falling (pooled OR of 
1.07,95% CI, 1.04 – 1.10). Like our findings, they also reported low measures of sensitivity in 
the balance measures used and concluded that the use of a balance measure alone is not 
appropriate when falls screening for people with Multiple Sclerosis. Given that studies from 
other populations56, 57 suggest that a balance measure alone may not have sufficient clinical 
utility to predict falls, we suggest those measures with significant differences on meta-
analysis should be considered for evaluation in future studies in combination with other 
clinical variables. 
 
There are a number of strengths associated with this systematic review. A robust 
methodological approach was employed to identify and select 33 unique studies relevant 
for inclusion which is higher than the previous reviews 4, 5 . We utilised rigorous methods to 
select and carefully appraise appropriate studies from a variety of databases. However, the 
findings need to be interpreted in the context of our study limitations. We originally 
proposed to investigate only prospective cohort studies; however, a scoping search 
indicated that there were a limited number of papers reporting this reference standard. We 
therefore included data from cross sectional studies comparing balance scores in people 
who do and do not report falls in this systematic review and meta-analysed that data. There 
was a lack of standardised conduct and reporting across the included studies with significant 
heterogeneity in the range of outcomes used. A strength is that we included all available 
studies, however a limitation is that some were of low methodological quality. The lack of a 
“cut off” or definition of “good” or “excellent” for the tools used meant that a clear 
rationale for excluding studies was not available and we did not use a sensitivity analysis to 
exclude certain studies from the meta-analyses.  
 
A further limitation of this review is that we did not specify the fall definition or faller 
classification as part of our inclusion criteria. Our results demonstrate a wide variety of fall 
definitions and faller classifications and this, and lack of consideration of clinical 
heterogeneity due to Multiple Sclerosis type or level of disability weakens the findings from 
our meta-analyses.  Only nine studies in this review used the gold standard of prospective 
falls recording with diaries as recommended by falls prevention networks such as the 
Prevention of Falls Network Europe 58 and the International Multiple Sclerosis Falls 
Prevention Research Network 59. We used a broad range of search terms to try and find all 
suitable studies, but the large numbers returned in our initial results may have resulted in 
suitable studies being missed at the screening stage.  We chose to exclude laboratory based 
measures of balance such as posturography using force plate platforms due to the lack of 
clinical applicability. However, there is a growing body of evidence on their discriminative 
ability and clinical utility in people with Multiple Sclerosis 60 and in the use of inertial sensors 
and instrumented gait tests to detect balance impairments in this population 61, 62.  
 
In conclusion, it is not currently possible to recommend any clinical balance measure for 
assessing falls risk in Multiple Sclerosis. From the small number of prospective studies 
presented in this review, it is clear that we do not have enough information about the 
predictive validity of the current measures commonly used to recommend any specific one. 
Given the multifactorial nature of falls, balance measures alone may not have adequate falls 
prediction ability. Similar to research on falls risk in older people 63, the use of quick 
screening questions rather than results of a lengthy assessment may more reliably identify 




 Meta-analysis shows fallers perform significantly worse than non-fallers on 
commonly used measures such as the Berg Balance Scale and Timed Up and Go, but 
the discriminative ability of these clinical measures is poor. 
 It is not possible to recommend any clinical balance measure for assessing falls risk in 
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Table 1a: Methodological quality of prospective cohort studies 
Study ID RISK OF BIAS 
 
APPLICABILITY CONCERNS OVERALL RISK 
OF BIAS 
 PATIENT   
SELECTION 
INDEX TEST REFERENCE 
STANDARD 
FLOW AND TIMING PATIENT 
SELECTION 
 
INDEX TEST REFERENCE 
STANDARD 
 
Cameron 2013 17     ?      
Dibble 2013 20      ?      
Gunn 2013 21   ?    ?     ?   
Hoang 2016 25   ?    ?   ?    ?    ? 
Kasser 2014 22    ?   ?      
Nilsagard 2009 23     ?      
Prosperini 2013 24      ?      
Tajali 2017 18     ?      
Vister 2017 19   ?    ?     ?    ? 
 








Table 1b: Methodological quality of cross sectional studies 
Study ID Selection 1, 
Representativeness 































 *  **     3 
Carling 2016 
47
  *  **   * * 5 
Cattaneo 2002 
28 
* *  ** * * * * 8 
Cattaneo 2006 
6 
* *  **   * * 6 
Cattaneo 2012 
27 
*   **   * * 5 
Cattaneo 2016 
43 
* * * **   * * 7 
Coote 2013 
44 
* *  ** * * * * 8 
Ganesan 2015 
41
 *   **   * * 5 
Forsberg 2013 
29 
*  * * **   * * 7 
Forsberg 2016 
45 
* * * **   * * 7 
Jacobs 2012 
30 
*   *   * * 4 
Kalron 2013 
31 
* *  ** *  * * 7 
Kalron 2014 
32 




 *  **   * * 5 






 *  **   * * 5 
Kalron 2017 
42
  *  **   * * 5 
Kanekar 2013 
33 
*   ** * * * * 7 
Nilsagard 2012 
34 
* *  **   *  5 
Ross 2016 
35 
* * * **   * * 7 
Sosnoff 2011 
8 
* *  ** *  * * 7 
Sung 2016 
46 
* *  **   * * 6 
Van Vliet 2015 
36 
* *  **   * * 6 
Ytterberg 2013 
37 









Table 2: Discriminative Ability and Clinical Utility of Clinical Measures in Prospective Cohort Studies 




Activities Balance Confidence 
Scale 
 
Falls Efficacy Scale 
International 
0.69 (p = 0.02) 
 
 
















Activities Balance Confidence 
Scale 
 
Berg Balance Scale  
 
Timed Up and Go 
 
Functional Reach Test 
 
























































62% 62% 2.0 
Kasser 2014 
22 
Survey of Activities and Fear NR NR NR NR 




Four Square Step Test 
 
Timed up and Go Cognitive 
 























Berg Balance Scale NR 32% (18-48) 87% (75-94) ≥ 44 
Tajali 2017 
18
 Falls Efficacy Scale 
International 
 
Timed Up and Go 
 
Activities Balance Confidence 
Scale 
0.89 (p ˂ 0.0001) 
 
 
0.65 (p = 0.014) 
 





















 Physiological Profile 
Assessment 
 



















AUC = area under the receiver operating characteristic curve statistic, NR = not reported. The p value or 95% confidence interval is given in brackets 
after the value, where reported.  
















































Studies excluded from 
abstract screening 
(n=10,418) 
Total number of studies identified 














Full text examined for eligibility  
N=67 
Studies included in systematic review 
for qualitative review, N = 33 
Studies included in quantitative 
synthesis (meta-analysis), N= 21 
Data missing/ insufficient for 
meta-analysis (N = 12) 
 
 




Study population duplicated 
(N=3) 
 
Figure 2a: Mean difference in Berg balance score between Fallers and Non-Fallers 
 
Figure 2b: Mean difference in Dynamic Gait Index between Fallers and Non-Fallers 
 
 
Figure 2c: Mean difference in Timed Up and Go test between Fallers and Non-Fallers 
 




Figure 2e: Mean difference in Mini-BESTest scores between Fallers and Non-Fallers 
 
 




















Online Appendix 1: MOOSE Checklist for Meta-analyses of Observational 
Studies 
 
Item No Recommendation 
Reported on 
Page No 
Reporting of background should include 
1 Problem definition 5 
2 Hypothesis statement 6 
3 Description of study outcome(s) 6 
4 Type of exposure or intervention used 6 
5 Type of study designs used 6 
6 Study population 6 
Reporting of search strategy should include 
7 Qualifications of searchers (eg, librarians and investigators) 6 
8 
Search strategy, including time period included in the synthesis and key 
words 
6 & online 
appendix 2 
9 Effort to include all available studies, including contact with authors 6 
10 Databases and registries searched 6 
11 
Search software used, name and version, including special features used 
(eg, explosion) 
6 
12 Use of hand searching (eg, reference lists of obtained articles) N/A 
13 List of citations located and those excluded, including justification N/A 
14 Method of addressing articles published in languages other than English N/A 
15 Method of handling abstracts and unpublished studies N/A 
16 Description of any contact with authors 7 
Reporting of methods should include 
17 
Description of relevance or appropriateness of studies assembled for 
assessing the hypothesis to be tested 
7 
18 
Rationale for the selection and coding of data (eg, sound clinical 
principles or convenience) 
7 
19 
Documentation of how data were classified and coded (eg, multiple 
raters, blinding and interrater reliability) 
7 
20 
Assessment of confounding (eg, comparability of cases and controls in 
studies where appropriate) 
N/A 
21 
Assessment of study quality, including blinding of quality assessors, 
stratification or regression on possible predictors of study results 
8 
22 Assessment of heterogeneity 8,9 
23 
Description of statistical methods (eg, complete description of fixed or 
random effects models, justification of whether the chosen models 
account for predictors of study results, dose-response models, or 
cumulative meta-analysis) in sufficient detail to be replicated 
9 
24 Provision of appropriate tables and graphics 
Tables 1 and 2, 
Figures 1 and 2 
Reporting of results should include 


















27 Results of sensitivity testing (eg, subgroup analysis) N/A 
28 Indication of statistical uncertainty of findings 13 




Reporting of discussion should include 
29 Quantitative assessment of bias (eg, publication bias) N/A 
30 
Justification for exclusion (eg, exclusion of non-English language 
citations) 
N/A 
31 Assessment of quality of included studies 16 
Reporting of conclusions should include 
32 Consideration of alternative explanations for observed results 15 
33 
Generalization of the conclusions (ie, appropriate for the data presented 
and within the domain of the literature review) 
16 
34 Guidelines for future research 17 
35 Disclosure of funding source 2 
Online Appendix 2: Search Strategy 
 
P = Population or Patient group:  people with Multiple Sclerosis 
I = Intervention: not applicable 
C = Comparator: clinical measure of balance 
O = Outcomes: method of falls reporting to classify as faller or non-faller  




Types of Research (following evidence hierarchy) 
o Cohort studies – with prospective falls monitoring 
o Primary research – RCTs (baseline data) 




o No limit on start date -  October 2017 
 
Language 




















Record sheet of searches 
 
Database and Date Searched Search Terms Number Retrieved Number of hits 
Medline, date – 15/03/17 #1 Multiple Sclerosis  
#2 MS  
#3 Acute Fulminating Sclerosis  
#4 Disseminated  
#5 (#1 OR #2 OR #3 OR #4)  
#6 Balance 
#7 Postural control  
#8 Imbalance  
#9 Postural instability 
#10 Stability  
#11 (#6 OR #7 OR #8 OR #9 OR 
#10)  
#12 Fall* 
#13 Fall risk 
#14 (#12 OR #13) 
#15 (#5 AND #11 AND #14)  
487 results 41 abstracts screened. 
23 studies suitable for inclusion (3 











  Online Appendix 3: Descriptive characteristics of prospective cohort studies 
Author, Year 
Study Design 
Eligibility Criteria  Recruited Assessment Measures of 
Falls and Balance 
Faller Definition and Classification 
Cameron et 





1. Mild to moderate Multiple 
Sclerosis. 
2. No clinically significant relapse 
in past 30 days. 
3. Able to complete a written 
daily record of falls for 6 months. 
 
Exclusion Criteria:  
1. Self-reported condition other 
than Multiple Sclerosis known to 
affect balance/gait. 
2. Unable to follow instructions 
in English. 
3. Unhealed fractures or other 
conditions that could cause 
injury during balance testing. 
4. Blindness 
5. Unable to walk more than 100 
metres 
52 people with Multiple 
Sclerosis:  
94% had relapse remitting 
form,  
Mean age 39.8 (8.4), Male: 
Female=17:35,  
Mean Disease Duration 6.3 
(5.6),  
Mean Expanded Disability 
Status scale 2.8 (1.5),  
Faller: Non-faller = 37: 15 
Falls record-prospective 
reporting using monthly fall 
calendars for 6 months, also 
retrospective recall for past 
2 and 12 months. 
Activities-specific Balance 
Confidence Scale and Falls 
Efficacy Scale international.  
Fall defined as an unexpected 
event that results in the person ending up 




Faller = person with 1 or more falls.  
Dibble et al, 




Inclusion Criteria:  
1. Able to walk 25 m 
independently without rest (with 
or without a mobility aid). 
2. Willingness to complete 
balance examinations and to 
complete falls record for a 12-
month period. 
 
38 people with Multiple 
Sclerosis: 
Mean age of fallers 53.83 
(9.67), mean age of non-
fallers 53.26 (11), 
Expanded Disability Status 
Scale mean 4.74 (1.29) in 
fallers and 4.33 (2.0) in 
non-fallers. 
Prospective falls diary (over 
12 months), retrospective 




Berg balance scale, 
Timed Up and Go, 
Dynamic Gait Index. 
Fall defined as an 
event in which the individual 
unintentionally came to rest on 
the ground or a lower surface, not as the 
result of a major intrinsic 
event (e.g. heart attack) or an 
overwhelming 
extrinsic event (e.g. ice). 
 
Exclusion Criteria:  
1. Other medical conditions that 
prevented their participation in 
the study. 
2. Refusal to be contacted for 
phone follow up regarding falls 
events. 
Disease duration in fallers 
group 14.0 (10.03), disease 
duration in non-fallers 
14.37 (10.95).  
Fallers: Non- fallers = 23: 
15 
Faller = person with 2 or more falls. 
Gunn et al, 





1. Expanded Disability Status 
Scale score of between 3.5 and 




1. Unable to effectively give 
informed consent. 
2. Co-morbidities that may 
significantly impact on balance. 
 
148 people with Multiple 
Sclerosis:  
Mean age 57 (10),  
Male: Female= 34:114,  
Relapse remitting= 42, 
Secondary Progressive = 
66, 
Primary progressive= 37, 
Benign= 2, 
Malignant= 1, 
Use of a walking aid, N= 
110 
Faller: Non- faller = 104: 
44 
Expanded Disability Status 
Scale values reported in 
individual breakdown, no 
mean reported. 
 
Prospective falls recall (falls 
diaries for 3 months post 
assessment),  




Fall defined as a 
slip or trip in which the person lost balance 
and landed on the 
floor or ground or lower level. 
 
 
Faller = person with 2 or more falls. 
 






1. Diagnosed with Multiple 
Sclerosis using standardised 
criteria. 
2. Over age 18 
(Other varying criteria for the 
different sites- US, UK and 
Australian study sites all had 
slightly different criteria). 
 
Exclusion Criteria 
1. Inability to give informed 
consent or unable to follow 
instructions for study 
participation.  
416 people with Multiple 
Sclerosis: 
Mean age 51.5 (range 
from 21-84), 
Male: Female = 111: 305, 
Mean disease duration = 
13.7 years (9.9), 
Mean Expanded Disability 
Status scale = 4.03 (range 
0-6.5), 
62% had relapse remitting, 




Male: Female = 78:274, 




Prospective falls diaries for 3 
months. 
Different fall definitions were used for 
different test sites. For the 
Australian site a fall was defined as 
‘‘unintentionally 
coming to the ground or other lower level 
and other than a consequence of sustaining 
a violent 
blow, loss of consciousness, sudden onset 
of paralysis 
as in stroke or epileptic or seizure’’. For the 
UK and US sites a fall was defined as ‘‘a 
slip or trip in which participants came to 
rest on the 
ground or floor or lower level’’ 
 
Non frequent faller = 0 or 1 fall, frequent 
faller = 2 or more falls.  
Kasser et al, 





1. No relapse in prior 3 months. 
2. Independent activities of daily 
living and driving. 
3. Sufficient cognitive function to 
complete all questionnaires. 
 
99 people with Multiple 
Sclerosis: 
All female, 
Mean age of 50.5 (8.38), 
Expanded Disability Status 
scale mean 2.97 (1.3), 
Faller: Non-faller = 35:22 
(full data for N=67) 
Prospective falls recording 
for a 12-month period. 
The Survey of Activities and 
Fear of Falling in the Elderly. 
Fall defined as any 
unexpected loss of balance that resulted in 
whole body 
contact with the ground. 
 
Faller = person with 1 or more falls. 
Nilsagard et 





1. Expanded Disability Status 
scale score between 3.5 and 6. 
2. Age 18-75. 
 
Exclusion criteria  
1. Difficulty in understanding 
76 People with Multiple 
Sclerosis:  
Mean age of fallers 50 
(range 25-71) and of non-
fallers 50 (range 32-75),  
Male: Female=6:22 in the 
non-fallers group and 
Prospective falls recall (over 
3 month period) and also 
retrospective at end of the 3 
months.  
Berg balance scale, 
Four Square Step test, 
Timed Up and Go Cognitive. 




Faller = person with 1 or more falls 
questions or filling in the 
questionnaires. 
2. Evident hearing or visual 
deficit. 
13:35 in the fallers group,  
Median Expanded 
Disability Status scale of 
non-fallers 4.0 (range 3.0-
6.0) and of fallers 5.0 
(range 3.5-6.0),  
Walking aid use, N=14 in 
the non-fallers group and 
N=36 in the fallers group. 
Faller:  Non-faller = 48: 28 
 
Prosperini et 




Inclusion Criteria:  
1. Age from 18 to 55. 
2. Expanded Disability Status 
scale score of 0 to 5.5. 




1. Pregnancy.  
2. Severely blurred vision.  
3. Change in medication in the 
previous 3 months. 
4. Concomitant otological or 
vestibular disease (not related to 
Multiple Sclerosis). 
5. Cardiovascular and respiratory 
disorders. 
6. Psychiatric disorders. 
7. Severe cognitive impairment. 
100 People with Multiple 
Sclerosis:  
Mean age 38.2 (9.6), Male: 
Female =36:64,  
Median Expanded 
Disability Status scale 3.2 
(1.0-5.0),  
Mean disease duration 9.5 
(6.4) 
Faller: Non-faller = 41: 59 
 
Prospective falls recall (over 
3 months). 
Berg balance scale. 
 
Fall defined as an unexpected 
contact of any part of the body with the 
ground. 
 
















Inclusion Criteria:  
1. A definite diagnosis of MS as 
diagnosed by a neurologist. 
2. Expanded Disability Status 
84 People with Multiple 
Sclerosis:  
Mean age of fallers = 30.29 
(8.87) and of non-fallers = 
Prospective falls recall over 
6 months. 
 
Timed Up and Go test, 
Fall defined as any unexpected event that 
results in ending up on the ground, floor, or 
any lower surface. 
 
cohort scale score of 0 to 5.5. 
3. No clinical relapse in 30 days 
prior to testing.  
 
Exclusion Criteria: 
1. Self-report of other conditions 
known to affect balance and 
gait.  
2. Uncorrected visual 
impairment.  
3. Severe cognitive impairment. 
33.8 (7.83) 
Male: Female =7:36 in 
non-fallers and 15:26 in 
fallers,  
Mean Expanded Disability 
Status scale = 3.03 (1.29) 
for non-fallers and 4.14 
(1.00) for fallers,  
Mean disease duration 
4.02 (4.15) for non- fallers 
and 5.48 (5.19) for fallers,  
Faller: Non-faller = 41: 43 
Activities, Balance and 
Confidence scale, 
Falls Efficacy Scale 
International. 


















1. Diagnosed with Multiple 
Sclerosis using standardised 
criteria. 
2. Over age 18 
3. Able to walk 10 metres with or 
without a mobility aid. 




1. Inability to give informed 
consent or unable to follow 
instructions for study 
participation secondary to 
impaired cognition or 
insufficient English.  
210 People with Multiple 
Sclerosis:  
Mean age 50.8 (11.1), 
Male: Female =58:152,  
Mean disease duration 9.9 
(7.0), 
58% had relapse remitting 
Multiple Sclerosis, 
49% using a mobility aid. 
Faller: Non-faller = 126: 84 
 




Falls Efficacy Scale 
International.  
Fall defined as unintentionally coming to 
the ground or some lower level and other 
than as a consequence of sustaining a 
violent blow, loss of consciousness, sudden 
onset of paralysis as in stroke, or an 
epileptic seizure. 
 
Faller = person with 1 or more falls. 
Online Appendix 4: Descriptive characteristics of cross-sectional studies 
Author, year 
Study Design 
Eligibility Criteria  Recruited Assessment Measures of Falls 
and Balance 
Fall Definition and 
Classification 
Cameron et al, 2014 26 
 
Study design not 
reported. 
Not reported 56 people with Multiple 
Sclerosis:  
Fallers: Non-fallers = 28: 26 
Retrospective falls recall (over 
past 2 and 12 months), 
Mini-BESTest. 
Fall definition not stated. 
 
Faller classification not 
stated. 
Carling et al, 2016 47 
 
Baseline data from a 
Randomised Controlled 
trial  
Inclusion Criteria:  
1. Multiple Sclerosis 
diagnosis according to 
McDonald criteria 
2. Walking distance not 
exceeding 200m (with or 
without an aid) 
3. Able to transfer from 
chair to plinth with 
minimal assistance (to be 




1. Cognitive impairment 
limiting ability to 
participate in the study 
2. Recent medical care in 
the past 3 months related 
to walking impairment 
3. Balance rehab 
administered by a health 
professional in the past 30 
days 
4. On medication with 4-
aminopyridine in the past 
30 days. 
51 people with Multiple 
Sclerosis: 
Male: Female = 16:35 
12% had relapse remitting, 
63% had secondary 
progressive Multiple 
Sclerosis, 
Mean age 58 (10.24), 
Mean Expanded Disability 
Status score 6.11 (0.49) 
86% used a walking aid, 
Disease duration = 20.85 
years (12), 
53% reported retrospective 
falls history. 
Fallers: Non-fallers = 28:24 
Retrospective falls status 
reported at start of study (time 
period not stated), also 
prospective falls reporting but 
baseline data used based on 
retrospective faller/non-faller 
status.  
Berg balance scale. 
Timed Up and Go 
Falls Efficacy Scale International 
Fall 
defined as an unexpected 
event in which participants 
come to rest on the ground, 
floor, or lower level. 
 
Faller classification not 
specified. 




Inclusion Criteria:  
1. Able to walk 
independently or with a 
cane. 
2. No cognitive or 
orthopaedic impairments. 
 
50 people with Multiple 
Sclerosis:  
Mean age of fallers 40 
(11.1), mean age of non-
fallers 43.5 (11.6), 
 Male: Female=38:62 in the 
fallers, 53:47 in non-fallers,  
Mean disease duration 13.4 
(12.7) in fallers, 15.6 (12.2) 
in non-fallers,  
32% of non-fallers used a 
cane, 59% of fallers used a 
cane. 
Fallers: Non-fallers = 17:33 
Retrospective falls recall (2-
month period pre-assessment), 
Equiscale Test. 
No fall definition stated. 
 
 
Faller = person with 2 or 
more falls. 




1. Ability to stand 
independently more than 
3 seconds. 
2. Ability to walk for 6 m 
even with an assistive 
device. 
 
Exclusion Criteria:  
1. Cognitive impairment  
2. Visual problems or 
impairment of VIII cranial 
nerve. 
51 people with Multiple 
Sclerosis:  
Mean age 45.3 (18.1), 
Male: Female= 16:35,  
Mean disease duration 15.6 
(7.6),  
15 participants used a 
walking aid. 
Fallers: Non-fallers = 20: 31 
 
Retrospective falls recall (1-
month pre-assessment), 
Berg balance scale, 
Timed Up and Go, 
Dynamic Gait Index, 
Dizziness Handicap Inventory, 
Activities-specific Balance 
Confidence Scale. 
Fall defined as any event that 
led to an unexpected 




Faller classification not 
stated. 
Cattaneo et al, 2012 27 
 
Cross-sectional 
Inclusion Criteria:  
1. Ability to stand 
independently upright for 
30 seconds. 
2. Ability to walk for 6 m 
even with an assistive 
47 people with Multiple 
Sclerosis:  
Mean age 52.01 (12.01),  
Male: Female=20:27,  
Mean disease duration 17.0 
(9.9) 
Retrospective falls record (2 
months prior to assessment),  
Berg balance scale, 
Dynamic Gait Index. 
 
Fall defined as an unexpected 
contact of any part of 
the body except for the feet 
with the ground. 
 
Faller = person with 1 or 
device. Expanded Disability Status 
Scale median 5 (range 2.5-
7.5) 
Faller: Non-faller = 11: 26 
more falls.  
Cattaneo et al, 2016 43 
 
Baseline data from a 
randomised controlled 
trial. 
Inclusion Criteria:  
1. Ability to stand 
independently upright for 
30 seconds with eyes 
open. 
2. Ability to walk for 6 m 




1. Ability to maintain 
single leg stance for 10 
seconds. 
2. Ability to maintain 
tandem stance for 30 
seconds. 
3. Cognitive impairment 
that would limit 
participation in the 
assessment/intervention. 
 
119 people with Multiple 
Sclerosis:  
Mean age 48.9 (11.1) in the 
intervention group, 46.7 
(11.4) in the control,  
Male: Female=36:83,  
Mean disease duration 14 
(8.6) in the intervention 
group, 12.9 (10.4) in the 
control, 
Faller: Non-faller =28: 91 
 
Retrospective falls recall (over 
previous 2 months), 
Berg balance scale, 
Dynamic Gait Index, 
Timed Up and Go, 
Activities-specific Balance 
Confidence Scale. 
Fall defined as an episode of 
unintentionally coming to 
rest on the ground or lower 
surface that was not the 
result of dizziness, fainting, 
sustaining a violent blow, loss 





Faller = person with 1 or 
more falls. 
Frequent faller = person with 
2 or more falls.  
Coote et al, 2013 44 
 
Baseline and post 




No details given. 
These data were part of 
the baseline assessments 
of 1 arm of an exercise 
trial, the methods of which 
had been published 
previously. 
111 people with Multiple 
Sclerosis;  
Mean age of fallers 55.6 
(10.4), mean age of non 
fallers 54.7 (11.1),  
Male: Female=17:38 in the 
fallers group, 23:32 in the 
non-fallers, 
Mean disease duration 16.6 
(5) in the fallers, 14.1 (3) in 
non-fallers. 
Faller: Non-faller = 56: 55 
Retrospective falls recall (over 
past 3 months), 
Berg balance scale. 
 
Fall defined as an unexpected 
contact of any part of the 
body with the ground. 
 
 
Faller = person with 1 or 
more falls.  




1. Expanded Disability 
Status Scale score of 4. 
2. Able to stand and walk 
without any aid or orthosis 
at least 500 meters,  
3. No relapse within the 
last three months,  
4. Normal or corrected to 
normal vision 
 
Subjects without Multiple 
Sclerosis 
1. Age and gender 
matched to MS 
participants. 
 
18 people with Multiple 
Sclerosis: 
Mean age 52.7 (12.2) 
Male: Female=4:14,  
Mean disease duration 18.8 
(9.4)  
Faller: Non-faller = 8: 10 
Retrospective falls recall (over 
previous 12 months), 
Berg balance scale, 
Activities-specific Balance 
Confidence Scale. 
No fall definition stated. 
 
Faller = person with 2 or 
more falls. 





1. Subjectively and 
objectively experience 
balance and walking 
81 people with Multiple 
Sclerosis:  
Mean age 49 (11) 
Male: Female=19:62,  
Retrospective falls recall (over 
previous 2 months),  
Dynamic Gait Index, 
Timed Up and Go,  
Fall defined as an unexpected 
contact 
of any part of the body with 
the ground. 
limitations. 
2. Ability to walk 100 m 
with an assistive device 
(similar to Expanded 
Disability Status Scale 
score of 1.0 to 6.0). 
 
Exclusion criteria    
1. Cognitive dysfunction. 
2. Difficulty understanding 
Swedish that affected the 
completion of self-
reported scales. 
Mean disease duration 12.0 
(8)  
Relapse remitting form = 
53,  
Primary progressive form= 
4,  
Secondary progressive = 24 
Walking aid indoors, N= 12, 
Walking aid outdoors, N= 
38 
Faller: Non-faller = 30: 51 
 
Four square step test. 
 
 
Faller = person with 1 or 
more falls. 
 
Forsberg et al, 2016 45 
 




1. Definite Multiple 
Sclerosis diagnosis. 
2. Able to walk 100 m 
(with or without an aid). 
3. Able to get up from the 
floor with minimal 
assistance. 
4. Unable to maintain 
tandem stance position for 
30 seconds. 
 
Exclusion criteria    
1. Cognitive dysfunction. 
2. Difficulty understanding 
Swedish that affected the 
completion of self-
reported scales. 
73 people with Multiple 
Scerosis:  
Mean age of intervention 
group 52 (10) and of 
control group 56.3 (11). 
Male:Female=7:28 in the 
intervention group, 7:31 in 
the control group,  
Mean disease duration 15 
(9) in the intervention 
group and 16 (11) in the 
control, 
45% of the group had 
relapse remitting, 
Walking aid indoors, N= 12, 
Walking aid outdoors, N= 
44 
Faller: Non-faller = 38:49 
Retrospective falls recall (over 
previous 3 months), 
Berg balance scale, 
Four Square Step test, 
Timed Up and Go and Timed Up 
and Go cognitive, 
Functional gait Assessment, 
Activities-specific Balance 
Confidence Scale. 
Fall defined as an unexpected 
event in which the participant 
comes to rest on the ground, 
floor, or lower level. 
 
Faller classification not 
stated. 
Jacobs et al, 2012 30 
 
Inclusion Criteria:  
Subjects with Multiple 
13 people with Multiple 
Sclerosis:  
Retrospective falls recall (over 
previous 3 months),  




Status Scale score < 6. 
2. No uncorrected hearing 
or visual deficit. 
 
Subjects without Multiple 
Sclerosis 




2. No uncorrected hearing 
or visual deficit. 
3. Age and gender 
matched to the subjects 
with Multiple Sclerosis. 
Mean age 50 (95% CI 43-
56), 
Male: Female= 5:8,  
Mean disease duration 9.5 
(95%CI 6.75-12.25),  
Expanded Disability Status 
Scale Median 2.5 (range 0-
4.5). 










Faller = person with 1 or 
more falls. 
 
Kalron et al, 2013 31 
 
Cross-sectional 
Inclusion Criteria:  
1. Ability to walk without a 
mobility aid. 
2. A neurologist confirmed 
diagnosis of relapse 
remitting Multiple 
Sclerosis. 
3. Relapse free for at least 




1. Orthopaedic disorders 
affecting mobility 
2. Major depression or 
cognitive decline. 
107 people with Multiple 
Sclerosis:  
Mean age of fallers 45.3 
(12.4), mean age of non 
fallers 39.6 (10.8), 
Male: Female= 26:34 in the 
fallers group and 19:28 in 
the non-fallers, 
Mean disease duration in 
fallers 7.7 (7.7) and in non-
fallers 4.3 (6.5), 
Mean Expanded Disability 
Status scale in fallers 3.6 
(1.5) and in non-fallers 1.7 
(1.5). 
Faller: Non-faller = 52: 49 
Retrospective falls recall 
(previous 6 months),  
Falls Efficacy Scale International. 
 




Faller = person with 1 or 
more falls.  
3. Pregnancy. 








1. Neurologist confirmed 
diagnosis of relapse 
remitting Multiple 
Sclerosis.  
2. People with Multiple 
Sclerosis who had 
undergone computerised 
neuropsychological testing 
(as data retrospectively 
evaluated from a 
computerised database).  
3. People with Multiple 
Sclerosis who had filled 
out the self-report forms 
Multiple Sclerosis Walking 
Scale-12, Falls Efficacy 
Scale International, and 
falling status 
questionnaires. 
4. People with Multiple 
Sclerosis who had a lab 
based gait assessment 
using the GAITRite 
electronic mat. 
5. All cognitive, gait and 
self-reported forms 
completed within a 14-day 
range. 
101 people with Multiple 
Sclerosis:  
Mean age 40.2 (11.9), 
Male: Female=41:60,  
Mean disease duration 5.4 
(6.3), Mean Expanded 
Disability Status scale 3.0 
(1.8) (range 1.5-6). 
Faller: Non-faller = 60: 47 
 
Retrospective recall of falls (over 
1 year),  
Falls Efficacy Scale International. 
 
Fall defined as an event 
when the participant 
unintentionally came to rest 




Faller = person with 1 or 




2. Subjects with 
orthopaedic disorders that 
could affect mobility. 
3. Blurred vision. 
4. Cardiovascular 
disorders. 
5. On steroids or 
fampridine. 
6. No history of psychiatric 
problems. 






1. Definite diagnosis of 
Multiple Sclerosis. 
2. Expanded Disability 
Status Scale of less than 7. 
3. Able to walk at least 20 
m without a rest. 
4. Relapse free for the 
previous 30 days. 
 
Exclusion Criteria: 
1. Orthopaedic disorders 
affecting mobility. 
2. Pregnancy. 
3. Blurred vision. 
4. Cardiovascular or 
respiratory conditions. 
5. On steroids or 
fampridine. 
402 people with Multiple 
Sclerosis: 
Male: Female = 153:249, 
Mean age 42.1 (14.1), 
Mean Expanded Disability 
Status Scale 2.7 (1.7), 
Mean disease duration = 6 
years (7.4), 
97% had relapse remitting 
form. 
Faller: Non-faller = 165:192 
Retrospective falls recall (over 
the previous year), 
Timed Up and Go, 
Four Square Step test, 
Falls Efficacy Scale International. 
 
No fall definition stated. 
 
Faller = person with 2 or 
more falls. 
Kalron et al, 2016 40 Inclusion Criteria: 218 people with Multiple Retrospective falls recall (over Fall defined as an event 




1. Definite diagnosis of 
Multiple Sclerosis. 
2. Expanded Disability 
Status Scale of less than 6. 
3. Relapse free for the 
previous 30 days, 
4. Outcome measures 
assessed within a 3 month 




1. Orthopaedic disorders 
affecting mobility. 
2. Pregnancy. 
3. Blurred vision. 
4. Cardiovascular or 
respiratory conditions. 
5. On steroids or 
fampridine. 
Sclerosis: 
Male: Female = 85:133, 
Mean age 43.2 (13.5), 
Mean Expanded Disability 
Status Scale 3.1 (1.3), 
Mean disease duration = 
7.5years (7.7), 
Faller: Non-faller = 111: 
107, 
95% had relapse remitting 
form.  
the previous year), 
Falls Efficacy Scale International, 
Timed Up and Go,  
Four Square Step test. 
 
where the participant 
unintentionally came to rest 
on the ground or a lower 
level.  
 
Faller = person with 2 or 
more falls. 





1. Definite diagnosis of 
Multiple Sclerosis. 
2. Expanded Disability 
Status Scale of less than 6. 
3. Relapse free for the 
previous 30 days, 
4. Outcome measures 
assessed within a 3-month 




229 people with Multiple 
Sclerosis: 
Male: Female = 86:143, 
Mean age 43.4(12.4), 
Mean Expanded Disability 
Status Scale 1.7 (0.7), 
Mean disease duration = 
6.2 years (7.1), 
Faller: Non-faller = 110: 
119, 
94% had relapse remitting 
form. 
Retrospective falls recall (over 
the previous year), 
Falls Efficacy Scale International, 
Timed Up and Go. 
 
Fall defined as an event 
where the participant 
unintentionally came to rest 
on the ground or a lower 
level.  
 
Faller = person with 2 or 
more falls. 
1. Orthopaedic disorders 
affecting mobility. 
2. Pregnancy. 
3. Blurred vision. 
4. Cardiovascular or 
respiratory conditions. 
5. On steroids or 
fampridine. 





1. Definite diagnosis of 
Multiple Sclerosis. 
2. Expanded Disability 
Status Scale of less than 7 
or able to walk at least 20 
metres without rest. 
3. Relapse free for the 
previous 30 days, 
4. Outcome measures 
assessed within a 3-month 




1. Orthopaedic disorders 
affecting mobility. 
2. Pregnancy. 
3. Blurred vision. 
4. Cardiovascular or 
respiratory conditions. 
5. On steroids or 
fampridine. 
285 people with Multiple 
Sclerosis: 
Male: Female = 109:176, 
Mean age 44.5(13.4), 
Mean Expanded Disability 
Status Scale 3.5 (1.6), 
Mean disease duration = 
8.1 years (8.1), 
Faller: Non-faller = 126: 
104, 
92% had relapse remitting 
form. 
Retrospective falls recall (over 
the previous year), 
Falls Efficacy Scale International, 
Timed Up and Go, 
Four Square Step test.  
 
Fall was defined as an event 
where the participant came 
to rest unintentionally on the 
ground, floor or a lower level. 
 
 
Faller = person with 2 or 
more falls. 
Kanekar et al, 2013 36 
 
Inclusion Criteria:   
For people with Multiple 
12 people with Multiple 
Sclerosis:  
Retrospective falls recall (over 
past 6 months), 





1. relapse remitting 
Multiple Sclerosis only 
2. Normal or corrected to 
normal vision. 
3. Able to stand 
independently without any 
aid for at least 1 minute. 
 
No specific criteria given 
for healthy control group. 
Mean age 53.16 (13.38),  
Mean Expanded Disability 
Status Scale 2.3 (0.9),  
Male: Female=2:10 
Faller: Non-faller = 6: 6 
 
Berg balance scale, 





Faller = person with 2 or 
more falls. 





1. Self-perceived impaired 
balance and gait. 
2. Ability to walk at least 
100 m without rest but 




1. Inability to understand 
the instructions or fill in 
the rating scales. 
2. Ongoing relapse 
affecting balance. 
3. Another disease 
preventing them from 
completing the measures. 
84 people with Multiple 
Sclerosis:  
Median age 51 (range 42-
58),  
Male: Female=20:64,  
Median disease duration 
12(range 6-18),  
Use of mobility aid, N=56 




Retrospective falls recall (2 
months prior to assessment), 
Activities- specific Balance 
Confidence Scale,  
Timed Up and Go,  
Dynamic gait Index, 






Fall defined as an unexpected 
contact of any part of the 
body with the ground. 
 
 
Faller = person with 1 or 
more falls. 
 
Ross et al, 2016 38 
 
Cross sectional cohort 
Inclusion Criteria: 
1. Primary diagnosis of 
Multiple Sclerosis. 
2. Medically stable. 
3. Independently mobile 
52 people with Multiple 
Sclerosis: 
Mean age of total group 
45.73 (5.65), 
Male: Female = 15:37, 
Retrospective falls record over 
past 3 months, 
Mini-BESTest 
Berg balance scale. 
Fall defined as an unexpected 
event in which 
the participants came to rest 
on the ground, floor, or lower 
level. 
with or without an aid. 
4. Over the age of 18. 
Mean disease duration 
10.87 (8.48), 
Mobility aid use: 38% of the 
group, 
81% of the group had 
relapse remitting. 
Faller: Non-faller = 15: 37 
 
 
Faller classification not 
stated.  




Inclusion Criteria:  
1. Ability to walk 
independently, with a 
mobility aid if needed. 
2. Comprehension of 
written and spoken 
English. 
3. Relapse free for 30 days. 
 
 
52 people with Multiple 
Sclerosis:  
Mean age of fallers 56.3 
(9.7) and of non-fallers 49.1 
(12.1), Male: Female=8:44,  
Mean disease duration for 
fallers 16.9 (10.6) and for 
non-fallers 9.9 (6.3),  
Median Expanded Disability 
Status Scale for fallers 4.5 
(IQR 2.5) and for non-fallers 
3.0 (IQR 2.0), 
Mobility aid use in the 
fallers group was 50% and 
in non-fallers was 13%. 
Faller: Non-faller = 29: 23 
Retrospective falls recall (over 
previous 12 months), 
Timed Up and Go, 
Six spot step test. 
 
Fall defined as 
an event where the 
participant unintentionally 
came to rest on the 
ground or a lower level. 
 
 
Faller = person with 1 or 
more falls. 
 
Sung et al, 2016 46 
 
Secondary data analysis 
of baseline data from a 
randomised controlled 
trial. 
Inclusion Criteria:  
1. Neurologist confirmed 
diagnosis of Multiple 
Sclerosis. 
2. Ability to walk at least 
25 feet, with a mobility aid 
if needed. 
3. Comprehension of 
written and spoken 
English. 
92 people with Multiple 
Sclerosis:  
Mean age 59.1 (7.3), 
Male: Female=23: 69,  
Mean disease duration was 
15.6 (8.5),  
Median Expanded Disability 
Status Scale for the group 6 
(IQR 1.5), 
54% had relapse remitting, 
Retrospective falls recall (over 
previous 3 months), 
Berg balance scale. 
Fall defined as an event 
where the participant 
unintentionally 
came to rest on the ground or 




Faller classification not 
stated. 
4. Over age 18. 
 
Use of mobility aid N=64. 
Faller: Non-faller = 58:34 




1. Over age 18. 
2. Definite diagnosis of 
Multiple Sclerosis. 
3. Multiple Sclerosis 
disease steps 0-5. 
4. Able to stand 
unsupported for 30 
seconds. 
5. Able to walk 10 m with 
or without a mobility aid. 
 
Exclusion Criteria 
1. Inability to understand 
instructions for the 
assessment due to poor 
English or impaired 
cognition. 
210 people with Multiple 
Sclerosis: 
Mean age of 51 (11.1) 
Male:Female = 62:148 
Mean disease duration = 
12.68 (9.08) 
59.9% of group had relapse 
remitting, 
47% used a mobility aid 
Faller: Non-faller = 159:51 
 
Retrospective falls recall (over 
previous 12 months), 
Falls Efficacy Scale International. 
Fall defined as 
unintentionally coming to the 
ground or some 
lower level and other than as 
a consequence of sustaining 
a violent blow, loss of 
consciousness, sudden onset 




Faller = person with 1 or 
more falls. 




1. Living and registered as 
a resident in Stockholm. 
2. Clinical confirmation of 
Multiple Sclerosis 
diagnosis and informed of 
same. 
3. No other severe 




164 people with Multiple 
Sclerosis: 
Median age of fallers 52 
(IQR 43-58) and of non-
fallers 50 (IQR 42-60), 
Male: Female=20:42 in the 
fallers group and 24:76 in 
the non-fallers group,  
Mild Expanded Disability 
Status Scale (1-3.5), N=10 
in the fallers and 39 in the 
non-fallers, 
Moderate/severe Expanded 
Retrospective falls recall (over 
the previous 3 months), 





Fall defined as an individual 
coming to rest on the ground 
or at some other lower level. 
 
 
Faller = person with 1 or 
more falls. 
Disability Status Scale (4-
9.5), N=52 in the fallers and 
63 in the non-fallers. 
Faller: Non-faller = 62: 102 
 
 
 
 
 
 
 
 
 
